Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
Status:
Completed
Trial end date:
2017-05-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate the safety and efficacy of ZTI-01 (IV fosfomycin)
as non-inferior to piperacillin/tazobactam in overall success (clinical cure and
microbiologic eradication) for the treatment of hospitalized patients with complicated
urinary tract infections (cUTI) or acute pyelonephritis (AP).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nabriva Therapeutics AG Zavante Therapeutics
Collaborator:
Medpace, Inc.
Treatments:
Fosfomycin Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam